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Abstract
Background: Metastasis is a major cause of morbidity and mortality in breast cancer with tumor
cell invasion playing a crucial role in the metastatic process. PDK1 is a key molecule that couples
PI3K to cell proliferation and survival signals in response to growth factor receptor activation, and
is oncogenic when expressed in mouse mammary epithelial cells. We now present evidence
showing that PDK1-expressing cells exhibit enhanced anchorage-dependent and -independent cell
growth and are highly invasive when grown on Matrigel. These properties correlate with induction
of MMP-2 activity, increased MT1-MMP expression and a unique gene expression profile.
Methods: Invasion assays in Matrigel, MMP-2 zymogram analysis, gene microarray analysis and
mammary isografts were used to characterize the invasive and proliferative function of cells
expressing PDK1. Tissue microarray analysis of human breast cancers was used to measure PDK1
expression in invasive tumors by IHC.
Results: Enhanced invasion on Matrigel in PDK1-expressing cells was accompanied by increased
MMP-2 activity resulting from stabilization against proteasomal degradation. Increased MMP-2
activity was accompanied by elevated levels of MT1-MMP, which is involved in generating active
MMP-2. Gene microarray analysis identified increased expression of the ECM-associated genes
decorin and type I procollagen, whose gene products are substrates of MT1-MMP. Mammary fat
pad isografts of PDK1-expressing cells produced invasive adenocarcinomas. Tissue microarray
analysis of human invasive breast cancer indicated that PDK1pSer241 was strongly expressed in
90% of samples.
Conclusion: These results indicate that PDK1 serves as an important effector of mammary
epithelial cell growth and invasion in the transformed phenotype. PDK1 mediates its effect in part
by MT1-MMP induction, which in turn activates MMP-2 and modulates the ECM proteins decorin
and collagen. The presence of increased PDK1 expression in the majority of invasive breast cancers
suggests its importance in the metastatic process.
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Background
PDK1 was first identified as a protein-Ser/Thr kinase that
linked PI3K to Akt activation in response to growth factor
receptor stimulation [1,2]. PDK1 phosphorylates AGC
kinases such as Akt [3,4], PKC [5,6] and SGK [7,8] in the
activation domain, which is a prerequisite for catalytic
activity. PDK1 has been studied extensively with respect to
its structure, activity, substrate specificity and cellular
localization as a signaling molecule critical in the PI3K
pathway [9-12]. Tumorigenesis studies have demon-
strated that PDK1-expressing mouse mammary epithelial
cells (Comma/PDK1) form adenocarcinomas in syn-
geneic mice [13], and that transformation was related to
increased expression of PKCα and β-catenin activation,
and to downregulation of the breast tumor suppressor
caveolin-1 [13,14]. PDK1 has been found to serve as an
effective therapeutic target for inhibition of glioblastoma
growth [15].
Cancer mortality is due largely to distant metastases and
subsequent organ failure. Metastasis involves the degrada-
tion of the basement membrane and stromal ECM and
migration into adjoining blood vessels that results in
tumor growth at distant organ sites [16,17]. Degradation
of the basement membrane and ECM involve the secre-
tion of several proteases, such as one or more members of
the MMP family [18,19]. Among the more than 20 MMPs
that have been identified [20], MMP-2 has been described
as a negative prognostic marker of metastasis and disease-
free interval [21,22]. MMP-2 activation and ECM invasion
is regulated in Akt1-expressing cells in part by stabiliza-
tion against proteasomal degradation independently of
transformation [23]. Although PDK1 was shown previ-
ously to exhibit tumorigenic activity, direct evidence for
its involvement in invasion has not been reported. In the
present investigation, we show that expression of PDK1
strongly induced ECM invasion, MT1-MMP levels and
MMP-2 activity in mammary epithelial cells that was
dependent on PI3K activation. In addition, Comma/
PDK1 cells formed invasive adenocarcinomas in syn-
geneic mice, and was highly expressed in 90% of invasive
human breast cancers, suggesting that PDK1 may serve as
a prognostic indicator of metastasis, as well as a potential
therapeutic target.
Methods
Cells, antibodies and plasmids
Comma-1D mouse mammary epithelial cells were
obtained from Dr. Robert B. Dickson, Georgetown Uni-
versity. Comma-1D cells were retrovirally transduced with
either PDK1 (Comma/PDK1) or empty virus (Comma/
vector) [13] and maintained at 37°C under 5% CO2 in
DMEM/F12 medium supplemented with 5% FBS, 10 ng/
ml EGF and 5 µg/ml insulin. Human breast cancer cell
lines MDA-MB-231 and MCF-7 were obtained from the
Tissue Culture Shared Resource, LCCC. Rabbit polyclonal
anti-MMP-2 antibody and LY294002 were purchased
from EMD Biosciences (La Jolla, CA), rabbit polyclonal
antibodies to PDK1pSer241 and Akt1pSer473 were
obtained from Cell Signaling Technology (Beverly, MA),
and a rabbit polyclonal antibody against MT1-MMP was
purchased from Chemicon International (Temecula, CA).
The MMP-2 promoter reporter constructs 'WT' and 'D9'
[24] were generously provided by Dr. Etty Benveniste,
University of Alabama.
Boyden chamber assay
Invasion assays were carried out in a 48-well Boyden
Chamber (NeuroProbe Inc, Rockville, MD) equipped
with an 8 µm polycarbonate membrane coated with 20
µg/ml Matrigel (BD Biosciences, San Diego, CA). Cells
were serum-starved for 6 hr, and 50 µl containing 10,000
cells in serum-free medium supplemented with 0.1% BSA
were loaded into the upper chamber. The lower chamber
contained either medium supplemented with 15% FBS as
the chemoattractant or serum-free medium containing
0.1% BSA as a negative control. Cells were incubated at
37°C overnight, fixed in 4% formaldehyde for 15 min
and stained with Harris-modified hematoxylin (Fisher
Scientific, Pittsburgh, PA). Noninvading cells on the top
of the membrane were wiped off using a cotton swab, and
invading cells affixed to the underside of the membrane
were counted in 5 random areas. An equal number of
MDA-MB-231 cells were used as a positive control, and
invasion of Comma/PDK1 and Comma/vector cells were
expressed as a percentage of the number of MDA-MB-231
cells invading Matrigel.
Zymography
Cells were grown in 75-cm2 cell culture flasks for 48 hr,
washed twice with PBS, and incubated in serum-free
DMEM/F12 medium for 24 hr. In some instances, cells
were treated with 1 µM lactacystin for 24 hr prior to incu-
bation in serum-free medium [23]. Conditioned medium
was collected and concentrated using a YM-30 Centriplus
centrifugal filter (Mr 30,000 cutoff, Amicon, Bedford, MA)
as described [23]. Concentrates containing 2 µg protein
were loaded onto a 10% polyacrylamide gel containing
0.1% gelatin (Invitrogen Corp., Carlsbad, CA) and sepa-
rated by SDS-PAGE. After electrophoresis, the gel was
renatured in 2.5% Triton X-100 solution at room temper-
ature for 30 min with gentle agitation, equilibrated in
developing buffer (50 mM Tris-HCl, pH 7.4; 200 mM
NaCl, 5 mM CaCl2, 0.02% Brij35) at room temperature
for 30 min with gentle agitation, and incubated overnight
at 37°C in fresh developing buffer. Transparent bands of
gelatinolytic activity were visualized by staining with
0.5% Coomassie Blue R250. In some instances, samples
were treated with 1 mM APMA for 1 hr at 37°C prior to
zymogram analysis.BMC Cancer 2006, 6:77 http://www.biomedcentral.com/1471-2407/6/77
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Luciferase assay
Cells were grown in a 24-well plate (40,000 cells/well)
and transfected with 100 ng 'WT' or 'D9' MMP-2 promoter
plasmid [24] using Lipofectamine Plus reagent (Invitro-
gen Corp., Carlsbad, CA). Transfection efficiency was
monitored by cotransfection with 100 ng pEGFP-C1 (BD
Bioscience, Palo Alto, CA) and ≥ 50% efficiency was
observed in both cell lines. Luciferase activity was meas-
ured after 24 hr using the Luciferase Assay System
(Promega, Madison, WI).
Cell growth
Cells were seeded into a 96-well plate at 3,000 cells/well
in 200 µl growth medium, and cell growth was measured
24–72 hr later by sulforhodamine B (SRB) staining [25].
Briefly, at the time of harvest, cells were fixed by addition
of 50 µl cold 50% TCA for 1 hr at 4°C and washed five
times with tap water. Cells were stained by addition of 50
µl/well of 0.4% SRB in 1% acetic acid at room tempera-
ture for 30 min, and rinsed four times with 1% acetic acid
to remove unbound dye. SRB was solubilized in 50 µl of
10 mM Tris base (pH 10.5) for 5 min with agitation, and
absorbance at 560 nm read in a Cambridge 750 micro-
plate reader (Cambridge Technology, Inc, Cambridge,
MA).
Anchorage-independent cell growth
Cells were seeded in 200 µl growth medium into a Sigma-
cote-coated Ultra Low Cluster 96-well plate (Corning Life
Sciences, Acton, MA) at 16,000 cells/well. Viable cells
were measured 72 hr later using the CellTiter-Glo
(Promega) luciferase assay according to the manufac-
turer's protocol. Briefly, at the time of harvest, an equal
volume of CellTiter-Glo reagent was added to each well
and the plate incubated at room temperature for 15 min
with gentle agitation. An aliquot of 100 µl was taken from
each well and chemiluminescence determined in a
Berthold MicroLumat Plus luminometer.
Growth on collagen
A collagen gel solution (0.8 mg/ml) was prepared on ice
by addition of 1.8 ml rat tail type I collagen (4.3 mg/ml)
(BD Biosciences), 1.8 ml 1.8% NaHCO3 and 0.18 ml 10×
PBS to 6.3 ml serum-free DMEM/F12 medium. Collagen
solution (0.5 ml/well) was added to a 24-well plate and
allowed to solidify at room temperature for at least 2 hr.
Cells (50,000 cells in 1 ml growth medium) were added
to the surface of the collagen and incubated at 37°C in a
CO2 incubator for 7 days. Cells were photographed using
a Nikon SMZ-1500 EPI-Fluorescence Stereoscope, Micro-
scopy and Imaging Shared Resource, LCCC.
Isograft transplantation
Comma/Vector and Comma/PDK1 cells were trans-
planted into the cleared mammary fat pad of 3 week old
BALB/c mice as described [13]. Eight weeks after trans-
plantation, mice were sacrificed, and isografts were fixed
in 10% formalin in PBS, embedded in paraffin, and
stained with H&E by the Histopathology and Tissue
Shared Resource, LCCC. Tumor lysates were analyzed by
western blot for the expression of PDK1 as described [13].
Western blot analysis
Cell lysates containing 100 µg protein were separated in
10% polyacrylamide gels by SDS-PAGE, blotted onto
nitrocellulose (Optitran, Schleicher and Schuell, Keene,
NH) and analyzed with Akt1, Akt1pSer473, MT1-MMP
and β-actin antibodies. For western analysis of MMP-2,
concentrates of conditioned medium containing 2 µg pro-
tein were mixed with 5X Laemmli sample buffer under
nonreducing conditions at room temperature for 10 min,
and separated in 10% polyacrylamide gels by SDS-PAGE.
Samples were blotted onto nitrocellulose (Optitran, Sch-
leicher and Schuell) and analyzed with an anti-MMP-2
antibody.
Immunohistochemistry
Paraffin sections of human malignant and benign breast
tumors were obtained from the Histopathology and Tis-
sue Shared Resource, LCCC. Tissue microarrays of inva-
sive human breast cancers were obtained from the
Cooperative Breast Cancer Tissue Resource (CBCTR),
NIH. Slides consisted of 252 normal and breast cancer
samples consisting of 64 cores each of node-negative,
node-positive and metastatic cancers, 20 cores of DCIS
and 40 cores of normal breast tissue. Slides were baked at
56°C over night, deparaffinized in xylene for 10 min, and
rehydrated in 100%, 95% and 70% ethanol for 5 min
each. Antigen retrieval was achieved by steaming the
slides for 30 min in 1 mM EDTA, pH 8.0. Slides were
washed three times in PBS and blocked for 30 min in a
buffer containing 1% bovine serum albumin and 5% goat
serum in PBS. Slides were incubated at 4°C overnight with
rabbit anti-PDK1pSer241 diluted 1:50, washed five times
in PBS and incubated with biotinylated secondary anti-
body for 1 hr. Slides were washed five times in PBS and
antigen was visualized using ABC Vectastain and DAB as
substrate (Vector Labs, Burlingame, CA). Slides were
counterstained with Harris-modified hematoxylin (Fisher
Scientific, Pittsburgh, PA) and mounted in Permount.
Staining intensity was scored 0, +, ++ or +++ for absent,
low, medium or high, respectively.
Gene microarray
Total RNA was prepared from Comma/PDK1 or Comma/
vector cells using Trizol according to the manufacturers'
instructions (Invitrogen Corp., Carlsbad, CA). cRNA syn-
thesis was carried out using the Affymetrix protocol with
minor modifications as described [26]. Biotin-labeled
cRNA was fragmented at 94°C for 35 min and used forBMC Cancer 2006, 6:77 http://www.biomedcentral.com/1471-2407/6/77
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hybridization overnight to an Affymetrix MurineGenome
U74Av2 GeneChip®  representing more than 36,000
mouse genes and EST's by the Macromolecular Analysis
Shared Resource. The processed chips were scanned using
an Agilent Gene Array scanner, and grid alignment and
raw data generation was carried out using Affymetrix
GeneChip® 5.0 software. Each analysis was repeated three
times. The expression of genes that were either increased
or decreased at least 2-fold in both experiments were clus-
tered hierarchically.
qrt-PCR
Total RNA (2 µg) was pre-digested with DNase I (Invitro-
gen) for 15 min and initiated for cDNA synthesis with
superscript II RNaseH reverse transcriptase (Invitrogen)
and random primers following the manufacturer's proto-
col. qrt-PCR was performed in triplicate in an ABI-Prism
7700 sequencing instrument (Applied Biosystems, Foster
City, CA) using SYBR green I detection as described
[26,27]. The increase in fluorescent signal was associated
with exponential formation of PCR product during the
linear log phase. The threshold cycle (CT) value is the cycle
at which a significant increase in the reaction product is
first detected. The higher the initial amount of cDNA, the
sooner accumulated product is detected in the PCR proc-
ess, and the lower the CT value. The expression of each tar-
get gene was normalized to the expression of β-actin and
is presented as the ratio of the target gene to β-actin gene
calculated by 2-∆Ct, where ∆Ct = CtTarget-Ctβ-actin. Primers
used for qrt-PCR are listed in table 2.
Results
Comma/PDK1 cells were found previously to be tumori-
genic in syngeneic mice [13]. To further assess their phe-
notype, gene expression profiling was used to compare
control and PDK1-expressing cells (Fig 1). The expression
of 27 genes decreased and 21 genes increased in Comma/
PDK1 cells compared to control cells. Among the changes
in ECM-related gene expression associated with invasion
[28] were an 18-fold increase in decorin, an 11-fold
increase in type I procollagen and a 10-fold increase in
collagen VI, whose expression has been linked to mam-
mary tumorigenesis [29]. WDNM1, a putative breast can-
cer metastasis suppressor [30,31], was reduced 26-fold,
and the MMP-2 inhibitor, TIMP-3, was also decreased in
Comma/PDK1 cells. Several changes in gene expression
detected by microarray analysis were confirmed by qrt-
PCR (Table 1). There was close agreement between the
two methodologies with the exception of the results for
Lck. In the latter case, Lck expression was greater in
Comma/PDK1 cells as determined by qrt-PCR vs. micro-
array analysis, which likely reflected the extremely low
background and basal expression in control cells as
detected by qrt-PCR.
Ectopic expression of PDK1 in mammary epithelial cells
resulted in increased anchorage-dependent and -inde-
pendent growth (Fig. 2). Comma/PDK1 cells grew at twice
the rate of control cells on a plastic substrate, and even
greater differences were noted under conditions of
anchorage-independent growth in low adherence sil-
conized plates (Fig 2A). Comma/PDK1 cells also grew
avidly on collagen and formed an uneven monolayer with
areas of piled up cells, in contrast to control cells which
showed little growth under these conditions (Fig. 2B). The
growth characteristics of Comma/vector cells mirrored
those of human breast epithelial cell line MCF-10A,
whereas those of Comma/PDK1 were similar to MCF-7
and MDA-MB-231 breast cancer cells (Fig. 2B). The ability
of Comma/PDK1 cells to invade an ECM was also
Table 1: PDK1-induced gene expression by qrt-PCR
Cell line WDNM1 TIMP3 Lck Collagen VI
Comma/vector 144.9 ± 11.0 156.5 ± 6.0 0.005 ± 0.001 0.56 ± 0.02
Comma/PDK1 3.1 ± 0.1 84.6 ± 2.3 43.6 ± 1.3 4.4 ± 0.3
-fold change -46.7 -1.8 8,720 7.9
-fold change in microarray -26.1 -2.4 41.1 10.0
Values are expressed as the absolute mRNA levels present in Comma/PDK1 and Comma/vector cells in arbitrary units relative to the expression of 
β-actin. Each result is the mean ± S.E. of 3 determinations. The relative values from gene microarray analysis are shown for comparison
Table 2: 
Genes Forward primer (5' → 3') Reverse primer (5' → 3')
WDNM1 AGACAGCCACAGTCTTTGTTCTG GATCCATCTCCTGTGCATCGTTC
TIMP3 CCC TTT GGC ACT CTG GTC TA TCC TGT GTA CAT CTT GCC TTC ATA
Lck CAA GAA TCT GAG CCG TTA GGA GGA GAT GTA GAA GCC ACC GTT GT
Collagen VI CCA AAC CCA CGG GAC CTC AAA CTC ACT GGC AAA GCT GTA GAC C
β-Actin AGA GGG AAA TCG TGC GTG AC CAA TAG TGA TGA CCT GGC CGTBMC Cancer 2006, 6:77 http://www.biomedcentral.com/1471-2407/6/77
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Gene microarray analysis of Comma/PDK1 cells Figure 1
Gene microarray analysis of Comma/PDK1 cells. Total RNA from Comma/vector and Comma/PDK1 cells were used to pre-
pare biotin-labeled cRNA for hybridization as described in Methods. Results are expressed as the -fold change in expression 
normalized to β-actin expression.
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assessed using the Boyden chamber assay with Matrigel as
the ECM (Fig. 2C). Comma/PDK1 cells were found to be
highly invasive in comparison to control cells, and were
equally as invasive as MDA-MB-231 cells that were used as
a positive control.
To determine whether invasion was associated with MMP
activation, conditioned medium from Comma/PDK1 and
Comma/vector cells was concentrated and analyzed by
zymography with gelatin as the substrate (Fig. 3). Proteo-
lytic activities of approximately 100 and 72 kDa were
PDK1 increases anchorage-dependent and -independent cell growth and ECM invasion Figure 2
PDK1 increases anchorage-dependent and -independent cell growth and ECM invasion. A, Top panel, Cell growth on a plastic 
substrate was determined after 24–72 hr by SRB staining as described in Methods. Results are expressed as the OD560 at each 
time point. Lower panel, Anchorage-independent growth was determined by seeding cells in siliconized plates and determining 
growth after 72 hr by assay for ATP using luciferase as described in Methods. Results are expressed in units of luciferase activ-
ity. B, Cells were grown for 7 days on collagen-coated plates. Magnification 50×. C, Cells were grown on Matrigel in a Boyden 
chamber and cells invading through Matrigel were determined. Results are expressed as a percentage of MDA-MB-231 cells 
invading Matrigel run in parallel as a positive control, and represent the mean ± S.E. of three independent experiments.
B
C
e
l
l
 
I
n
v
a
s
i
o
n
 
(
%
 
o
f
 
M
D
A
-
M
B
-
2
3
1
)
0
20
40
60
80
100
120
140
MDA-MB-231
Comma/Vector
Comma/PDK1
C
A
0
0.2
0.4
0.6
0.8
1
1.2
1.4
24hs 48hs 72hs
O
D
 
5
6
0
Comma/SRĮ
Comma/PDK1
Anchorage-independent Growth, 72 hr
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
4k 8k 12k 16k
Cell number per well
L
u
c
i
f
e
r
a
s
e
 
A
c
t
i
v
i
t
y
Vector
PDK1BMC Cancer 2006, 6:77 http://www.biomedcentral.com/1471-2407/6/77
Page 7 of 12
(page number not for citation purposes)
present in the conditioned medium from both cell lines,
and the 72 kDa species was markedly increased in
Comma/PDK1 cells (Fig 3A). Induction of autocatalytic
processing with APMA resulted in the disappearance of
the 100 kDa activity and appearance of 72 and 66 kDa
species (Fig. 3A). Western blotting under non-reducing
conditions indicated that the 100 and 72 kDa activities
were proMMP-2 and MMP-2, respectively (Fig. 3B). The
influence of proteasomal degradation on MMP activity
was next tested with the proteasome inhibitor lactacystin
(Fig. 3C). Lactacystin markedly increased both proMMP-2
and MMP-2 activities in control cells, but had little or no
effect on the already high activity present in the condi-
tioned medium from Comma/PDK1 cells (Fig 3C). These
Overexpression of PDK1 increases MMP-2 activity and MT1-MMP Figure 3
Overexpression of PDK1 increases MMP-2 activity and MT1-MMP. A, Comma/Vector and Comma/PDK1 cells were grown and 
conditioned medium was concentrated and assayed for MMP activity by zymography in the present or absence of 1 mM APMA 
as described in Methods. Protein markers are indicated by their mass in kDa. B, Concentrates of conditioned medium 
described in A containing 2 µg protein were separated under non-reducing conditions by SDS-PAGE in 10% polyacrylamide 
gels, and blotted onto nitrocellulose and analyzed with an anti-MMP-2 antibody. C, Comma/Vector (Vector) and Comma/PDK1 
(PDK1) cells were incubated for 24 hr in the presence and absence of 1 µM lactacystin, followed by incubation in serum-free 
medium for 24 hr. Samples were assayed by zymography as in A. D, Cells were transfected with 'WT' or 'D9' MMP-2 promoter 
plasmids as described in Methods. Luciferase activity was measured after 24 hr and is expressed as the -fold change relative to 
control cells. Luciferase activity (light units) in control cells with the 'WT' and 'D9' plasmids was 2,970 and 6,520, respectively. 
E, Comma/Vector (Vector) and Comma/PDK1 (PDK1) cells were treated with or without lactacystin as in B and cell lysates ana-
lyzed by western blotting for levels of MT1-MMP.
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results suggest that PDK1 increased MMP-2 activity in part
by attenuating proteasomal degradation. In contrast,
PDK1 did not affect reporter gene activity under the con-
trol of the MMP-2 promoter [24] as determined with the
139 bp (D9) and 1,659 bp (WT) MMP-2 promoter
regions (Fig. 3D). Cells were also analyzed for MT1-MMP
expression since MMP-2 is processed to the catalytically
active form by MT1-MMP [32] (Fig. 3E). MT1-MMP levels
were markedly increased in PDK1-expressing cells, but
were not further increased by lactacystin treatment sug-
gesting that regulation of MT1-MMP expression may be
the primary mechanism by which PDK1 regulates MMP-2
activity.
To determine the influence of the PI3K/PDK1 signaling
pathway on MMP-2 activation, Comma/PDK1 cells were
treated with the PI3K inhibitor LY294002 (Fig. 4).
LY294002 reduced 72 kDa MMP-2 activity (Fig. 4A),
whereas treatment with either the MEK inhibitor U0126
or the p38 inhibitor SB203580 had no effect (results not
shown). In addition, the activity of the downstream PDK1
target, Akt, as determined by Akt1pSer473 expression was
inhibited to a similar extent as MMP-2 activity (Fig. 4B).
The invasive potential of Comma/PDK1 cells in vivo was
next determined by grafting cells into the cleared mam-
mary fat pad of syngeneic mice (Fig. 5). Comma/PDK1
cells grew into invasive and vascular poorly differentiated
adenocarcinomas within 8 weeks after transplantation, in
contrast to the normal mammary gland morphology pro-
duced by control cells.
As a measure of the significance of PDK1 expression in
breast cancer invasion, paraffin sections of malignant and
benign breast cancers were examined for PDK1pSer241
expression (Fig. 6A). A pilot study determined that paraf-
fin-embedded sections of a ductal breast carcinoma exhib-
ited strong staining for PDK1pSer241, whereas little or no
staining occurred in benign breast tumors. To obtain a
broader perspective of the significance of PDK1 expres-
sion in invasive breast cancer, tissue microarrays of node-
negative, node-positive and metastatic breast cancer spec-
imens were assessed for expression of PDK1pSer241 by
IHC (Fig. 6B,C). Ninety percent of all tumor samples
exhibited moderate to strong staining for PDK1pSer241,
with 42% of evaluable samples exhibiting strong expres-
sion (74/177 cores). These data further indicate that
PDK1 is associated with an invasive phenotype in breast
cancer.
Discussion
The present study demonstrates that PDK1 expression
confers a marked growth advantage to mammary epithe-
lial cells that was associated with increased ECM invasion,
Inhibition of PI3K reduces MMP expression in Comma/PDK1 cells Figure 4
Inhibition of PI3K reduces MMP expression in Comma/PDK1 cells. Cells were treated for 24 hr with 5–40 µM LY294002. A, 
Media was concentrated and assayed for MMP activity by zymography as described in Fig. 3. Bar graph represents a densito-
metric scan of the zymogram. B, Cells were lysed and analyzed by western blotting for levels of Akt, Akt1pS473 and β-actin. 
Bar graph represents a densitometric scan of the western blots normalized for β-actin levels.
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MMP-2 activity and MT1-MMP expression. Gene microar-
ray analysis additionally identified two known MT1-MMP
substrates known to be involved in growth and invasion,
decorin and type I procollagen [28]. MT1-MMP expres-
sion has been linked to invasive breast cancer and lymph
node and distant metastases [33,34], which is consistent
with the increased gene expression of two MT1-MMP
ECM-related substrates, type I collagen [28,35], and deco-
rin [36] in Comma/PDK1 cells. Thus, the invasive pheno-
type of Comma/PDK1 cells is closely associated with a
heretofore unrecognized phenotype associated with
increased MT1-MMP expression and MMP-2 activity.
Array analysis also detected increased collagen VI and
reduced WDNM1 and TIMP3 gene expression in PDK1-
expressing cells. Collagen VI has been previously linked to
mammary tumorigenesis [29], and loss of the tumor sup-
pressor WDNM1 is associated with rat mammary adeno-
carcinoma [31] and human breast cancer metastasis
[30,37]. We have previously linked the tumorigenic phe-
notype of Comma/PDK1 cells to the disappearance of
another breast cancer tumor suppressor, caveolin-1
[14,38]. Thus, reduced expression of two tumor suppres-
sor genes are associated with the PDK1 signaling pathway
that may contribute to the invasive and tumorigenic phe-
notype resulting from unregulated PDK1 expression.
Neoplastic transformation and invasion of isografts of Comma/PDK1 cells Figure 5
Neoplastic transformation and invasion of isografts of Comma/PDK1 cells. H&E stained paraffin-embedded tissue obtained 
from isografts of cells transduced with either empty virus (Ctl) or PDK1 (T1, T2, T3) 8 weeks after transplantation. Mammary 
isografts of control cells have normal lobuloalveolar ductal morphology with surrounding adipose tissue. Comma/PDK1 iso-
grafts produced poorly differentiated adenocarcinomas with solid cords of cells with little gland formation (T1), invasion of 
underlying skeletal muscle (T2) and vascularity (T3). Magnification: 100×.BMC Cancer 2006, 6:77 http://www.biomedcentral.com/1471-2407/6/77
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Immunohistochemical detection of PDK1pSer241 in breast cancer specimens Figure 6
Immunohistochemical detection of PDK1pSer241 in breast cancer specimens. A, IHC for PDK1pSer241 in paraffin blocks of 
benign (C,D) and malignant (A,B) breast tissue. Staining was conducted with either nonimmune IgG (B,D) or a PDK1pSer241 
antibody (A,C). B, Tissue microarray cores of low (+) expressing and high (+++) expressing breast cancers stained for 
PDK1pSer241. PDK1pSer241 was abundant in both the cytosol and nucleus of the carcinoma. C, A bar graph depicting the 
results in the tissue microarray analysis of 177 evaluable cores expressing either no (0), low (+1), medium (+2) or strong (+3) 
PDK1pSer241 staining of normal (normal), DCIS (DCIS), node negative (node (-)), node positive (node (+)) and metastatic (node 
distant) breast carcinomas.
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The present study demonstrates that PDK1 markedly
increases proliferation, particularly with collagen as a sub-
strate, which is known to induce growth arrest by inhibit-
ing the Ras/Erk pathway and cyclin D1 expression [39].
These results are consistent with activation of cyclin D1
downstream to β-catenin/TCF activation in Comma/
PDK1 cells [14]. Increased proliferation may also have
occurred through activation of the PI3K/Akt1 axis by
PDK1 [10,40,41], which accounts in part for increased
cyclin D1 expression [14], mammary hyperplasia in trans-
genic animal models [42] and invasion [23], but not
transformation per se [13]. Importantly, the proliferative
and invasive characteristics of PDK1-expressing cells were
recapitulated in vivo as mammary isografts, which attests
to the tumorigenic potential of the PDK1 signaling path-
way [13,14]. Of note were the similar invasion activity
between Comma/PDK1 cells and MDA-MB-231 breast
carcinoma cells, which are known for their metastatic
behavior [43-45].
MMP-2 activity is an important factor associated with
invasion. Overexpression of MMP-2 activity in MDA-MB-
231 cells increased invasion in vitro, as well as distant
metastases in nude mice [46], and high MMP-2 levels was
associated with metastatic breast tumors [21,22,47].
PDK1 modulated MMP-2 activity in part through stabili-
zation against proteasomal degradation, a mechanism
similar to that described for Akt1 and v-akt [23]. MMP-2
expression is linked to IGF-I signaling [48] and MT1-
MMP, which activates the proenzyme form of MMP-2,
and is upregulated via the PI3K/Akt1 pathway [32]. These
findings are consistent with the increased expression of
MT1-MMP in Comma/PDK1 cells since Akt is a down-
stream effector of PDK1, as well as the ability of LY294002
to block MMP-2 activation and inhibit Akt activity. Our
finding that PDK1 is activated in a large percentage of
invasive human breast cancers further suggests the impor-
tance of the PDK1 signaling pathway to the metastatic
phenotype.
Conclusion
The present study demonstrates that PDK1 expression in
mammary epithelial cells confers not only a growth
advantage, but also an invasive phenotype characterized
by increased MMP-2 activity and MT1-MMP expression.
These results further define the tumorigenic and invasive
processes elicited by PDK1, and suggest a fundamental
new role for the PDK1 pathway in breast cancer growth
and metastasis.
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